James Sullivan
Chief Tech/Sci/R&D Officer chez ENGENE HOLDINGS INC.
Fortune : - $ au 31/03/2024
Profil
James C.
Sullivan is currently the Chief Scientific Officer at enGene Holdings, Inc. since 2023 and at enGene, Inc. since 2022.
Previously, he served as the Executive Director & Head-Translational Biology at Sana Biotechnology, Inc. from 2019 to 2021 and as the Senior Vice President-Pulmonary Discovery at Translate Bio, Inc. in 2021 to 2022.
He holds a doctorate degree from Boston University, an undergraduate degree from Boston College, and a graduate degree from University College Dublin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENGENE HOLDINGS INC.
-.--% | 01/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de James Sullivan
| Sociétés | Poste | Début |
|---|---|---|
| ENGENE HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 01/11/2023 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 01/02/2022 |
Anciens postes connus de James Sullivan
| Sociétés | Poste | Fin |
|---|---|---|
| TRANSLATE BIO, INC. | Corporate Officer/Principal | 01/02/2022 |
| SANA BIOTECHNOLOGY, INC. | Director/Board Member | 01/01/2021 |
Formation de James Sullivan
| Boston University | Doctorate Degree |
| Boston College | Undergraduate Degree |
| University College Dublin | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
| enGene Holdings, Inc. |
